Last reviewed · How we verify

NCT05059899: WALKSTRONG

Home-based Circuit Training for People With Intermittent Claudication

Completed NA Last updated 22 August 2023
What this trial tests

NA trial testing Exercise group in Peripheral Artery Disease in 30 participants. Completed in 26 June 2023.

Timeline
9 May 2022
Primary endpoint
26 June 2023
26 June 2023

Quick facts

Lead sponsorCoventry University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date9 May 2022
Primary completion26 June 2023
Estimated completion26 June 2023
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Coventry University

Who can join

18 and older, any sex, with Peripheral Artery Disease or Intermittent Claudication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the feasibility of undertaking a randomised controlled trial investigating the effectiveness of a 12-week home-based exercise programme for people with intermittent claudication.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. "It's put a routine and regimen in my life" - Participant experiences with a programme of community walking and home-based circuit training for intermittent claudication.
    Waddell A, Denton F, Powell R, Broom DR, et al · · 2024 · PMID 39645388 · DOI 10.1016/j.jvn.2024.09.003

Verify or expand the search:

Other trials of Exercise group

Trials testing the same drug.

Other recruiting trials for Peripheral Artery Disease

Currently open trials in the same condition.

Other Coventry University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05059899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing